Giuliani Jacopo, Mandarà Marta, Muraro Marco, Rampello Elvira, Franceschetto Antonella, Fiorica Francesco
Department of Oncology, Azienda ULSS 9 Scaligera, 37122 Legnago, VR, Italy.
J Clin Med. 2024 Sep 14;13(18):5456. doi: 10.3390/jcm13185456.
The optimal management of rectal cancer remains a subject of ongoing research. This meta-analysis of individual patient data assessed the benefit of chemoradiotherapy (fluorouracil-based) in local advanced rectal cancer: disease-free survival and overall survival. We pooled the data of 6145 patients from 24 studies of rectal cancer who received neoadjuvant radiotherapy with concomitant fluorouracil or capecitabine and surgery. The PRISMA 2020 abstract checklist was followed. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. The median OS was not reached; the mean survival time was 135.4 months (127.9-141.5). The median DFS was 176.9 months, and the mean disease-free survival time was 122.6 months (111.7-131.9). We provided a benchmark for future studies on rectal cancer treatment. The present results can be used in decision-making for locally advanced rectal cancer patients.
直肠癌的最佳治疗方案仍是一个正在研究的课题。这项对个体患者数据的荟萃分析评估了（基于氟尿嘧啶的）放化疗在局部晚期直肠癌中的益处：无病生存期和总生存期。我们汇总了来自24项直肠癌研究的6145例患者的数据，这些患者接受了新辅助放疗并同时使用氟尿嘧啶或卡培他滨以及手术治疗。遵循了PRISMA 2020摘要清单。使用已发表的Kaplan-Meier曲线的算法重建个体参与者的生存期。总生存期未达到中位数；平均生存时间为135.4个月（127.9 - 141.5）。无病生存期的中位数为176.9个月，平均无病生存时间为122.6个月（111.7 - 131.9）。我们为未来的直肠癌治疗研究提供了一个基准。目前的结果可用于局部晚期直肠癌患者的决策制定。
